Cytokine signal suppressor (SOCS) 1-1478 CA/del gene polymorphism in Turkish patients with polycystic ovary syndrome

References

• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. 2005. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 90:1929–1935.
   PubMed Web of Science ®Google Scholar
• Chan HC, Ke LY, Chang LL, Liu CC, Hung YH, Lin CH, et al. 2010. Suppressor of cytokine signaling 1 gene expression and polymorphisms in systemic lupus erythematosus. Lupus 19:696–702.
   PubMed Web of Science ®Google Scholar
• Chan HC, Ke LY, Liu CC, Chang LL, Tsai WC, Liu HW, et al. 2010. Increased expression of suppressor of cytokine signaling 1 mRNA in patients with rheumatoid arthritis. Kaohsiung Journal of Medical Sciences 26:290–298.
   PubMed Web of Science ®Google Scholar
• Chong MM, Metcalf D, Jamieson E, Alexander WS, Kay TV. 2005. Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood 106:1668–1675.
   PubMed Web of Science ®Google Scholar
• El-Mazny A, Abou-Salem N, El-Sherbiny W, El-Mazny A. 2010. Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome. International Journal of Gynecology & Obstetrics 109:239–241.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. 2005. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocrine Reviews 26:251–282.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Naka T. 2003. Regulation of cytokine signaling by SOCS family molecules. Trends in Immunology 24:659–666.
   PubMed Web of Science ®Google Scholar
• Galluzzo A, Amato MC, Giordano C. 2008. Insulin resistance and polycystic ovary syndrome. Nutrition, Metabolism & Cardiovascular Diseases 18:511–508.
   PubMed Web of Science ®Google Scholar
• Goodman N, Bledsoe M, Cobin R, Futterweit W, Goldzieher J, Petak S, et al. 2001. American Association of Clinical Endocrinologists Hyperandrogenism Guidelines. Endocrine Practice 7:120–134.
   PubMedGoogle Scholar
• Harada M, Nakashima K, Hirota T, Shimizu M, Doi S, Fujita K, et al. 2007. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. American Journal of Respiratory Cell and Molecular Biology 36:491–496.
   PubMed Web of Science ®Google Scholar
• Howard JK, Flier JS. 2006. Attenuation of leptin and insulin signaling by SOCS proteins. Trends in Endocrinology and Metabolism 17:365–371.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Hull RL, Utzschneider KM. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–846.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 111:607–613.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, San Millán JL, Escobar-Morreale HF. 2006. Genomic variants in polycystic ovary syndrome. Clinica Chimica Acta 366:14–26.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419.
   PubMed Web of Science ®Google Scholar
• Ni R, Ihara K, Miyako K, Takemoto M, Ishimura M, Kohno H, et al. 2006. Association study of polymorphisms in SOCS family genes with type 1 diabetes mellitus. International Journal of Immunogenetics 33:7–10.
   PubMed Web of Science ®Google Scholar
• Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. 2008. Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecologica 60:39–51.
   PubMedGoogle Scholar
• Repaci A, Gambineri A, Pasquali R. 2011. The role of low-grade inflammation in the polycystic ovary syndrome. Molecular and Cellular Endocrinology 335:30–41.
   PubMed Web of Science ®Google Scholar
• Roa Barrios M, Arata-Bellabarba G, Valeri L, Velázquez-Maldonado E. 2009. Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome. Endocrinología y Nutrición 56:59–65.
   PubMedGoogle Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and Sterility 81:19–25.
   Web of Science ®Google Scholar
• Slowińska-Srzednicka J, Zgliczyński S, Wierzbicki M, Srzednicki M, Stopińska-Gluszak U, Zgliczyński W, et al. 1991. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. Journal of Endocrinological Investigation 14:569–575.
   PubMed Web of Science ®Google Scholar
• Tan JC, Rabkin R. 2005. Suppressors of cytokine signaling in health and disease. Pediatric Nephrology 20:567–575.
   PubMed Web of Science ®Google Scholar
• Tellechea ML, Steinhardt AP, Rodriguez G, Taverna MJ, Poskus E, Frechtel G. 2013. Common variants in SOCS7 gene predict obesity, disturbances in lipid metabolism and insulin resistance. Nutrition, Metabolism & Cardiovascular Diseases 23:424–431.
   PubMed Web of Science ®Google Scholar
• Yildiz BO, Yarali H, Oguz H, Bayraktar M. 2003. Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism 88:2031–2036.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. 2005. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Research & Therapy 7:100–110.
   PubMed Web of Science ®Google Scholar